演題抄録

ポスター

開催概要
開催回
第56回・2018年・横浜
 

食道扁平上皮癌における上皮間葉移行(EMT)とPD-L1発現

演題番号 : P70-2

[筆頭演者]
演者)佐久間 芽衣:1 
[共同演者]
Aung Kyi Thar Min:1、岡山 洋和:1、齋藤 元伸:1、早瀬 傑:1、多田 武志:1、花山 寛之:1、佐瀬 善一郎:1、大木 進司:1、佐藤 雄亮:2、本山 悟:2、三村 耕作:1、河野 浩二:1

1:福島県立医科大学・消化管外科、2:秋田大学・胸部外科

 

Esophageal squamous cell carcinoma (ESCC) is an aggressive tumor, and it is urgently needed to develop novel therapeutic strategies including immunotherapy. Immunotherapy with inhibition of PD-1/PD-L1 interaction by therapeutic mAb would be a new promising treatment strategy for variety of cancer types including ESCC. In the present study, we investigated the up-regulation of the programmed death ligand 1 (PD-L1) due to epithelial-mesenchymal transition (EMT) in ESCC by IHC in the clinical tumor samples of both Tissue Microarray (TMA) samples (n = 177) and whole tissue samples (n = 21). Definition of EMT phenotype is as low E-cadherin expression, and for PD-L1, IHC was evaluated from intensity and proportion of membranous staining with or without cytoplasmic staining. As a result, the IHC stains of ESCC showed that PD-L1 expression on tumor cells was positively correlated with EMT status in TMA samples (p = 0.0004) and whole tissue samples (p = 0.0029). In conclusion, our in vivo study clearly demonstrated that PD-L1 expression was up-regulated in mesenchymal type tumors of ESCC. These findings provide a strong rationale for the clinical use of anti-PD-1/anti-PD-L1 monoclonal antibodies for advanced ESCC patients.

キーワード

臓器別:食道

手法別:腫瘍免疫

前へ戻る